1
|
Topalov NE, Mayr D, Kuhn C, Leutbecher A, Scherer C, Kraus FBT, Tauber CV, Beyer S, Meister S, Hester A, Kolben T, Burges A, Mahner S, Trillsch F, Kessler M, Jeschke U, Czogalla B. Characterization and prognostic impact of ACTBL2-positive tumor-infiltrating leukocytes in epithelial ovarian cancer. Sci Rep 2023; 13:22620. [PMID: 38114558 PMCID: PMC10730610 DOI: 10.1038/s41598-023-49286-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Accepted: 12/06/2023] [Indexed: 12/21/2023] Open
Abstract
Actin beta-like 2 (ACTBL2) was recently identified as a new mediator of migration in ovarian cancer cells. Yet, its impact on tumor-infiltrating and thus migrating leukocytes (TILs) remains to date unknown. This study characterizes the subset of ACTBL2-expressing TILs in epithelial ovarian cancer (EOC) and elucidates their prognostic influence on the overall survival of EOC patients with special regard to different histological subtypes. Comprehensive immunohistochemical analyses of Tissue-Microarrays of 156 ovarian cancer patients revealed, that a tumor infiltration by ACTBL2-positive leukocytes was significantly associated with an improved overall survival (OS) (61.2 vs. 34.4 months; p = 0.006) and was identified as an independent prognostic factor (HR = 0.556; p = 0.038). This significant survival benefit was particularly evident in patients with low-grade serous carcinoma (OS: median not reached vs. 15.6 months, p < 0.001; HR = 0.058, p = 0.018). In the present cohort, ACTBL2-positive TILs were mainly composed of CD44-positive cytotoxic T-cells (CD8+) and macrophages (CD68+), as depicted by double-immunofluorescence and various immunohistochemical serial staining. Our results provide significant evidence of the prognostic impact and cellular composition of ACTBL2-expressing TILs in EOC. Complementary studies are required to analyze the underlying molecular mechanisms of ACTBL2 as a marker for activated migrating leukocytes and to further characterize its immunological impact on ovarian carcinogenesis.
Collapse
Affiliation(s)
- N E Topalov
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
| | - D Mayr
- Institute of Pathology, Faculty of Medicine, University Hospital, LMU Munich, Munich, Germany
| | - C Kuhn
- Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany
| | - A Leutbecher
- Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
| | - C Scherer
- Department of Medicine I, University Hospital, LMU Munich, Munich, Germany
| | - F B T Kraus
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - C V Tauber
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - S Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - S Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - A Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - T Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - A Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - S Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - F Trillsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - M Kessler
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - U Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
- Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany
| | - B Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
2
|
Oliva M, Kaganer V, Pudelski M, Meister S, Tahraoui A, Geelhaar L, Brandt O, Auzelle T. A route for the top-down fabrication of ordered ultrathin GaN nanowires. Nanotechnology 2023; 34:205301. [PMID: 36745915 DOI: 10.1088/1361-6528/acb949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Accepted: 02/06/2023] [Indexed: 06/18/2023]
Abstract
We introduce a facile route for the top-down fabrication of ordered arrays of GaN nanowires with aspect ratios exceeding 10 and diameters below 20 nm. Highly uniform thin GaN nanowires are first obtained by lithographic patterning a bilayer Ni/SiNxhard mask, followed by a combination of dry and wet etching in KOH. The SiNxis found to work as an etch stop during wet etching, which eases reproducibility. Arrays with nanowire diameters down to (33 ± 5) nm can be achieved with a uniformity suitable for photonic applications. Next, a scheme for digital etching is demonstrated to further reduce the nanowire diameter down to 5 nm. However, nanowire breaking or bundling is observed for diameters below ≈20 nm, an effect that is associated to capillary forces acting on the nanowires during sample drying in air. Explicit calculations of the nanowire buckling states under capillary forces indicate that nanowire breaking is favored by the incomplete wetting of water on the substrate surface during drying. The observation of intense nanowire photoluminescence at room-temperature indicates good compatibility of the fabrication route with optoelectronic applications. The process can be principally applied to any GaN/SiNxnanostructures and allows regrowth after removal of the SiNxmask.
Collapse
Affiliation(s)
- M Oliva
- Paul-Drude-Institut für Festkörperelektronik, Leibniz-Institut im Forschungsverbund Berlin e.V., Hausvogteiplatz 5-7, D-10117 Berlin, Germany
| | - V Kaganer
- Paul-Drude-Institut für Festkörperelektronik, Leibniz-Institut im Forschungsverbund Berlin e.V., Hausvogteiplatz 5-7, D-10117 Berlin, Germany
| | - M Pudelski
- Paul-Drude-Institut für Festkörperelektronik, Leibniz-Institut im Forschungsverbund Berlin e.V., Hausvogteiplatz 5-7, D-10117 Berlin, Germany
| | - S Meister
- Paul-Drude-Institut für Festkörperelektronik, Leibniz-Institut im Forschungsverbund Berlin e.V., Hausvogteiplatz 5-7, D-10117 Berlin, Germany
| | - A Tahraoui
- Paul-Drude-Institut für Festkörperelektronik, Leibniz-Institut im Forschungsverbund Berlin e.V., Hausvogteiplatz 5-7, D-10117 Berlin, Germany
| | - L Geelhaar
- Paul-Drude-Institut für Festkörperelektronik, Leibniz-Institut im Forschungsverbund Berlin e.V., Hausvogteiplatz 5-7, D-10117 Berlin, Germany
| | - O Brandt
- Paul-Drude-Institut für Festkörperelektronik, Leibniz-Institut im Forschungsverbund Berlin e.V., Hausvogteiplatz 5-7, D-10117 Berlin, Germany
| | - T Auzelle
- Paul-Drude-Institut für Festkörperelektronik, Leibniz-Institut im Forschungsverbund Berlin e.V., Hausvogteiplatz 5-7, D-10117 Berlin, Germany
| |
Collapse
|
3
|
Hahn L, Meister S, Mannewitz M, Beyer S, Corradini S, Hasbargen U, Mahner S, Jeschke U, Kolben T, Burges A. Gal-2 führt zu einer Erhöhung von H3K4me3 und H3K9ac
in Trophoblasten und in der Präeklampsie. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- L Hahn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie,
Klinikum der LMU München
| | - U Hasbargen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
- Klinik für Frauenheilkunde und Geburtshilfe,
Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| |
Collapse
|
4
|
Müller L, Mitter S, Mannewitz M, Keilmann L, Meister S, Kolben MT, Schmoeckel E, Burges A, Trillsch F, Czogalla B, Jeschke U, Kessler M, Mahner S, Kolben T, Beyer S. Die Blutgruppenantigene SLeX, SLeA and Lewis Y als potenziell prognostische Faktoren im Endometrium- und Zervixkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Affiliation(s)
- L Müller
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mitter
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Mannewitz
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Keilmann
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Meister
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E Schmoeckel
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - A Burges
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - B Czogalla
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - M Kessler
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
5
|
Dreyer EM, Meister S, Thomann M, Hahn L, Keilmann L, Beyer S, Mayer C, Prins G, Hermelink K, Hasbargen U, Mahner S, Kolben T. Einfluss der psychischen Belastung durch die COVID-19-Pandemie auf
das Auftreten von Wochenbettdepressionen und die Relevanz individueller
Stressbewältigungs-Strategien. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- E-M Dreyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - M Thomann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - L Hahn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - L Keilmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - C Mayer
- Fakultät für Psychologie, Universität
Würzburg
| | - G Prins
- Fakultät für Sozialwissenschaften, Universität
Augsburg
| | - K Hermelink
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - U Hasbargen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| |
Collapse
|
6
|
Mitter S, Müller L, Mannewitz M, Keilmann L, Meister S, Kolben MT, Schmoeckel E, Burges A, Trillsch F, Czogalla B, Mahner S, Kessler M, Jeschke U, Kolben T, Beyer S. RIG-I – Expression als negativer prognostischer Faktor im Endometriumkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- S Mitter
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Müller
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Mannewitz
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Keilmann
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Meister
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E Schmoeckel
- Pathologisches Institut, Universitätsklinikum der LMU, München
| | - A Burges
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - B Czogalla
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Kessler
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
7
|
Appi E, Papadopoulou CC, Mapa JL, Jusko C, Mosel P, Schoenberg A, Stock J, Feigl T, Ališauskas S, Lang T, Heyl CM, Manschwetus B, Brachmanski M, Braune M, Lindenblatt H, Trost F, Meister S, Schoch P, Trabattoni A, Calegari F, Treusch R, Moshammer R, Hartl I, Morgner U, Kovacev M. Synchronized beamline at FLASH2 based on high-order harmonic generation for two-color dynamics studies. Rev Sci Instrum 2021; 92:123004. [PMID: 34972439 DOI: 10.1063/5.0063225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Accepted: 11/26/2021] [Indexed: 06/14/2023]
Abstract
We present the design, integration, and operation of the novel vacuum ultraviolet (VUV) beamline installed at the free-electron laser (FEL) FLASH. The VUV source is based on high-order harmonic generation (HHG) in gas and is driven by an optical laser system synchronized with the timing structure of the FEL. Ultrashort pulses in the spectral range from 10 to 40 eV are coupled with the FEL in the beamline FL26, which features a reaction microscope (REMI) permanent endstation for time-resolved studies of ultrafast dynamics in atomic and molecular targets. The connection of the high-pressure gas HHG source to the ultra-high vacuum FEL beamline requires a compact and reliable system, able to encounter the challenging vacuum requirements and coupling conditions. First commissioning results show the successful operation of the beamline, reaching a VUV focused beam size of about 20 µm at the REMI endstation. Proof-of-principle photo-electron momentum measurements in argon indicate the source capabilities for future two-color pump-probe experiments.
Collapse
Affiliation(s)
- E Appi
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover 30167, Germany
| | | | - J L Mapa
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover 30167, Germany
| | - C Jusko
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover 30167, Germany
| | - P Mosel
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover 30167, Germany
| | | | - J Stock
- Carl Zeiss AG, Oberkochen 73446, Germany
| | - T Feigl
- optiX fab GmbH, Jena 07745, Germany
| | | | - T Lang
- DESY, Hamburg 22607, Germany
| | | | | | | | | | - H Lindenblatt
- Max-Planck-Institut für Kernphysik, Heidelberg 69117, Germany
| | - F Trost
- Max-Planck-Institut für Kernphysik, Heidelberg 69117, Germany
| | - S Meister
- Max-Planck-Institut für Kernphysik, Heidelberg 69117, Germany
| | - P Schoch
- Institut für Umweltphysik, Ruprecht-Karls-Universität Heidelberg, Heidelberg 69120, Germany
| | - A Trabattoni
- Center for Free-Electron Laser Science CFEL, DESY, Hamburg 22607, Germany
| | - F Calegari
- Center for Free-Electron Laser Science CFEL, DESY, Hamburg 22607, Germany
| | | | - R Moshammer
- Max-Planck-Institut für Kernphysik, Heidelberg 69117, Germany
| | - I Hartl
- DESY, Hamburg 22607, Germany
| | - U Morgner
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover 30167, Germany
| | - M Kovacev
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover 30167, Germany
| |
Collapse
|
8
|
Dokic I, Klein C, Moustafa M, Meister S, Mein S, Kopp B, Tessonnier T, Hasheminasab S, Wei Q, Schlegel J, Nowrouzi A, Schwager C, Mairani A, Zimmermann A, Zenke F, Blaukat A, Debus J, Abdollahi A. Efficient Eradication of NSCLC by Combined DNAPK Inhibition and Carbon Ion Radiotherapy via Modulation of Tumor Invasion and Microenvironment - Beyond Direct Radiosensitization. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Mannewitz M, Beyer S, Meister S, Kolben T, Schmoeckel E, Mayr D, Anz D, Perleberg C, Burges A, Trillsch F, Vattai A, Czogalla B, Corradini S, Mahner S, Jeschke U, Kolben T. Impact of monocyte- and macrophage- derived CCL22 on endometrial cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T.M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - D Anz
- Arbeitsgruppe Immunregulation, Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - C Perleberg
- Arbeitsgruppe Immunregulation, Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
10
|
Hahn L, Beyer S, Kolben T, Schmoeckel E, Mayr D, Anz D, Kuhn C, Vattai A, Hester A, Corradini S, Hasbargen U, Mahner S, Jeschke U, Meister S, Kolben T. Verminderte Rekrutierung regulatorischer T-Zellen bei erhöhter CCL22-Expression in der Präeklampsie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Hahn
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Beyer
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T.M Kolben
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - E Schmoeckel
- Klinikum der LMU München, Pathologisches Institut
| | - D Mayr
- Klinikum der LMU München, Pathologisches Institut
| | - D Anz
- Klinikum der LMU München, Center of Integrated Protein Science Munich (CIPS-M), Division of Clinical Pharmacology
| | - C Kuhn
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Vattai
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Hester
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Corradini
- Klinikum der LMU München, Klinik und Poliklinik für Strahlentherapie und Radioonkologie
| | - U Hasbargen
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Jeschke
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Meister
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T Kolben
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
11
|
Kellner I, Beyer S, Hasbargen U, Mahner S, Hester A, Vattai A, Jeschke U, Corradini S, Kolben T, Kolben T, Meister S. Die Immunreaktion im Abortgeschehen – Interaktion von Immunzellen untereinander und mit der Umgebung im Bereich der Plazenta und der Zusammenhang mit dezidualen Mikrothrombosen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- I.M Kellner
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Beyer
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Hasbargen
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Hester
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Vattai
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Jeschke
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Corradini
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Strahlentherapie und Radioonkologie
| | - T.M Kolben
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T Kolben
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Meister
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | | |
Collapse
|
12
|
Wehrmann M, Beyer S, Meister S, Kolben TM, Schmoeckel E, Mayr D, Burges A, Trillsch F, Vattai A, Hester A, Mahner S, Jeschke U, Kolben T. Galectin-8 and -9 as prognostic factors for cervical cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Wehrmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
13
|
Kremer N, Vattai A, Schmöckel E, Meister S, Beyer S, Czogalla B, Fürst S, Mahner S, Corradini S, Jeschke U, Kolben T, Kolben T. Rolle der Makrophagendifferenzierung und -interaktion mit regulatorischen T-Zellen bei der Progression und Regression der HPV-induzierten Zervixdysplasie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- N Kremer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - A.S Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - E Schmöckel
- Pathologisches Institut, Medizinische Fakultät, LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Fürst
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Corradini
- Klinik für Strahlentherapie, Klinikum der Universität München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
- Klinik und für Frauenheilkunde und Geburtshilfe, Klinikum der Universität Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| |
Collapse
|
14
|
Wehrmann M, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Burges A, Trillsch F, Vattai A, Hester A, Mahner S, Jeschke U, Beyer S. Gal-8, Gal-9, Histone H3-Acetyl-K9, Histone H3-Trimethyl-K4 and Glucocorticoid Receptor as possible prognostic markers in endometrial cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Wehrmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
15
|
Meister S, Hahn L, Beyer S, Kolben T, Schmoeckel E, Mayr D, Vattai A, Hester A, Corradini S, Hasbargen U, Mahner S, Jeschke U, Kolben T. Die Rolle epigenetischer Modifikationen in der Präeklampsie im Zusammenhang mit PPARγ (Peroxisom-Proliferator-aktivierter Rezeptor-γ) und Galectin-2. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Meister
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - L Hahn
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Beyer
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T.M Kolben
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - E Schmoeckel
- Ludwig-Maximilians-Universität München, Pathologisches Institut der Ludwig-Maximilians-Universität München
| | - D Mayr
- Ludwig-Maximilians-Universität München, Pathologisches Institut der Ludwig-Maximilians-Universität München
| | - A Vattai
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Hester
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Corradini
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Strahlentherapie und Radioonkologie
| | - U Hasbargen
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Jeschke
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
- Universitätsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtshilfe
| | - T Kolben
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
16
|
Meister S, Kolben T, Beyer S, Hutter S, Kuhn C, Mayr D, Solano M, Jegen M, Hasbargen U, Mahner S, Arck P, Jeschke U. Geschlechtsspezifische epigenetische Aktivierung von Genen bei intrauteriner Wachstumsretardierung (IUGR). Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Meister
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T Kolben
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Beyer
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Hutter
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - C Kuhn
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - D Mayr
- Ludwig-Maximilians-Universität München, Pathologisches Institut der Ludwig-Maximilians-Universität München
| | - M.E Solano
- Uniklinikum Hamburg-Eppendorf, Geburtshilfe und Gynäkologie
| | - M Jegen
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Hasbargen
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - P Arck
- Uniklinikum Hamburg-Eppendorf, Geburtshilfe und Gynäkologie
| | - U Jeschke
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
- Universitätsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
17
|
Beyer S, Fangfang C, Meister S, Czogalla B, Kolben TM, Hester A, Burges A, Trillsch F, Schmoeckel E, Mayr D, Mayerhofer A, Mahner S, Jeschke U, Kolben T. Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - C Fangfang
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Mayerhofer
- Biomedizinisches Zentrum München (BMC), Zellbioloige, Anatomie III, LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
18
|
Berger L, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Ditsch N, Beyer S. Expression of H3K4me3 and H3K9ac in breast cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Berger
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
19
|
Mannewitz M, Kolben T, Meister S, Kolben T, Schmoeckel E, Mayr D, Anz D, Perleberg C, Burges A, Trillsch F, Vattai A, Corradini S, Czogalla B, Mahner S, Jeschke U, Beyer S. Regulatory T-cells as a potential target to overcome immune evasion in endometrial cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T.M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - D Anz
- Arbeitsgruppe Immunregulation, Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - C Perleberg
- Arbeitsgruppe Immunregulation, Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
20
|
Kellner I, Beyer S, Hasbargen U, Mahner S, Hester A, Vattai A, Jeschke U, Kolben TM, Kolben T, Meister S. Die Immunreaktion im Abortgeschehen – Interaktion von Immunzellen untereinander und mit der Umgebung im Bereich der Plazenta und der Zusammenhang mit dezidualen Mikrothrombosen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- I Kellner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München
| | - U Hasbargen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München
| |
Collapse
|
21
|
Mannewitz M, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Anz D, Perleberg C, Burges A, Trillsch F, Vattai A, Czogalla B, Corradini S, Mahner S, Jeschke U, Beyer S. Einfluss von Monozyten- und Makrophagen-sezerniertem CCL22 auf das Endometriumkarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - D Anz
- Arbeitsgruppe Immunregulation (CIPS-M), Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - C Perleberg
- Arbeitsgruppe Immunregulation (CIPS-M), Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
22
|
Wehrmann M, Beyer S, Meister S, Kolben TM, Schmoeckel E, Mayr D, Burges A, Trillsch F, Vattai A, Hester A, Corradini S, Mahner S, Jeschke U, Kolben T. Galektin 8 und Galektin 9 als Prognostische Faktoren im Zervix-Karzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Wehrmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
23
|
Kremer N, Vattai A, Schmoeckel E, Meister S, Beyer S, Czogalla B, Fürst S, Mahner S, Corradini S, Jeschke U, Kolben T, Kolben TM. Rolle der Makrophagendifferenzierung und -interaktion mit regulatorischen T-Zellen bei der Progression und Regression der HPV-induzierten Zervixdysplasie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- N Kremer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - E Schmoeckel
- Pathologisches Institut, Medizinische Fakultät, LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Fürst
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Corradini
- Klinik für Strahlentherapie, Klinikum der Universität München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
- Klinik und für Frauenheilkunde und Geburtshilfe, Klinikum der Universität Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| |
Collapse
|
24
|
Berger L, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Ditsch N, Beyer S. Expression von H3K4me3 und H3K9ac in Brustkrebs. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Berger
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
25
|
Mannewitz M, Beyer S, Meister S, Kolben TM, Schmoeckel E, Mayr D, Anz D, Perleberg C, Burges A, Trillsch F, Vattai A, Czogalla B, Corradini S, Mahner S, Jeschke U, Kolben T. Regulatorische T-Zellen als potentielles Target zur Überwindung der Immunevasion bei Endometriumkarzinomen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - D Anz
- Arbeitsgruppe Immunregulation (CIPS-M), Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - C Perleberg
- Arbeitsgruppe Immunregulation (CIPS-M), Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
26
|
Wehrmann M, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Burges A, Trillsch F, Vattai A, Hester A, Corradini S, Mahner S, Jeschke U, Beyer S. Gal-8, Gal-9, H3K9ac, H3K4me3 und der Glukokortikoidrezeptor als prognostische Marker im Endometriumkarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Wehrmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
27
|
Abstract
Digitalization cannot be understood as an off-the-shelf product, bought as a one-time purchase in a warehouse. It rather requires a constantly developing vision, which comes with a continuous transformation process, hand in hand with strategic innovation management. Thus, digitalization means understanding the digital maturity level of an enterprise and the digital skills of the employees. Besides an investment in products, a successful digitalization process also necessitates consideration of the cost to release employees from their obligations in order to contribute to the process as well as for a dedicated and continuing staff training and education program. While digitalization in Germany is underdeveloped regarding both the national health infrastructure and the level of digitalization in hospitals, German clinics are recognizing more and more the importance of digitalization and are initiating digitalization strategies. In this regard, we can learn from our European partners, who have partially established advanced and innovative solutions. Looking into these flagship projects can help to see potentials and to identify valuable building blocks for our own strategy.
Collapse
Affiliation(s)
- W Deiters
- Hochschule für Gesundheit, Gesundheitscampus 6-8, 44801, Bochum, Deutschland.
| | - A Burmann
- Fraunhofer-Institut für Software- und Systemtechnik, Dortmund, Deutschland
| | - S Meister
- Fraunhofer-Institut für Software- und Systemtechnik, Dortmund, Deutschland
| |
Collapse
|
28
|
Meister S, Beyer S, Mahner S, Jeschke U, Kolben TM, Kolben T. Die Immunreaktion im Abortgeschehen – Interaktion von Immunzellen untereinander und mit der Umgebung im Bereich der Plazenta und der Zusammenhang mit dezidualen Mikrothrombosen. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| |
Collapse
|
29
|
Kolben TM, Meister S, Rogatsch E, Vattai A, Hester A, Kuhn C, Schmoeckel E, Mahner S, Jeschke U, Kolben T. Die Expression von PPARγ in trophoblastärem Gewebe spontaner und habitueller Aborte im Vergleich zu gesunden Schwangerschaften. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - E Rogatsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - C Kuhn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - E Schmoeckel
- Pathologisches Institut, LMU München, München, Deutschland
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| |
Collapse
|
30
|
Beyer S, Meister S, Czogalla B, Kolben TM, Burges A, Trillsch F, Schmöckel E, Mayr D, Mayerhofer A, Mahner S, Jeschke U, Kolben T. Sitruin1-Expression im Endometrium-Karzinom: eine immunhistochemische Analyse. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - E Schmöckel
- Pathologisches Institut, LMU München, München, Deutschland
| | - D Mayr
- Pathologisches Institut, LMU München, München, Deutschland
| | - A Mayerhofer
- Biomedizinisches Zentrum München (BMC), Zellbiologie, Anatomie III, LMU München, Planegg, Martinsried, Deutschland
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| |
Collapse
|
31
|
Norcross NR, Wilson C, Baragaña B, Hallyburton I, Osuna‐Cabello M, Norval S, Riley J, Fletcher D, Sinden R, Delves M, Ruecker A, Duffy S, Meister S, Antonova‐Koch Y, Crespo B, de Cózar C, Sanz LM, Gamo FJ, Avery VM, Frearson JA, Gray DW, Fairlamb AH, Winzeler EA, Waterson D, Campbell SF, Willis PA, Read KD, Gilbert IH. Substituted Aminoacetamides as Novel Leads for Malaria Treatment. ChemMedChem 2019; 14:1329-1335. [PMID: 31188540 PMCID: PMC6899483 DOI: 10.1002/cmdc.201900329] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2019] [Indexed: 01/29/2023]
Abstract
Herein we describe the optimization of a phenotypic hit against Plasmodium falciparum based on an aminoacetamide scaffold. This led to N-(3-chloro-4-fluorophenyl)-2-methyl-2-{[4-methyl-3-(morpholinosulfonyl)phenyl]amino}propanamide (compound 28) with low-nanomolar activity against the intraerythrocytic stages of the malaria parasite, and which was found to be inactive in a mammalian cell counter-screen up to 25 μm. Inhibition of gametes in the dual gamete activation assay suggests that this family of compounds may also have transmission blocking capabilities. Whilst we were unable to optimize the aqueous solubility and microsomal stability to a point at which the aminoacetamides would be suitable for in vivo pharmacokinetic and efficacy studies, compound 28 displayed excellent antimalarial potency and selectivity; it could therefore serve as a suitable chemical tool for drug target identification.
Collapse
Affiliation(s)
- Neil R. Norcross
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - Caroline Wilson
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - Beatriz Baragaña
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - Irene Hallyburton
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - Maria Osuna‐Cabello
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - Suzanne Norval
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - Jennifer Riley
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - Daniel Fletcher
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | | | | | | | - Sandra Duffy
- Discovery BiologyGriffith Institute for Drug DiscoveryGriffith UniversityNathanQueensland4111Australia
| | - Stephan Meister
- Department of PediatricsUniversity of California San Diego School of Medicine9500 Gilman Drive 0741La JollaCA92093USA
| | - Yevgeniya Antonova‐Koch
- Department of PediatricsUniversity of California San Diego School of Medicine9500 Gilman Drive 0741La JollaCA92093USA
| | - Benigno Crespo
- GlaxoSmithKline, Diseases of the Developing World – Tres Cantos Medicines Development Campusc/ Severo Ochoa 2, Tres Cantos28760MadridSpain
| | - Cristina de Cózar
- GlaxoSmithKline, Diseases of the Developing World – Tres Cantos Medicines Development Campusc/ Severo Ochoa 2, Tres Cantos28760MadridSpain
| | - Laura M. Sanz
- GlaxoSmithKline, Diseases of the Developing World – Tres Cantos Medicines Development Campusc/ Severo Ochoa 2, Tres Cantos28760MadridSpain
| | - Francisco Javier Gamo
- GlaxoSmithKline, Diseases of the Developing World – Tres Cantos Medicines Development Campusc/ Severo Ochoa 2, Tres Cantos28760MadridSpain
| | - Vicky M. Avery
- Discovery BiologyGriffith Institute for Drug DiscoveryGriffith UniversityNathanQueensland4111Australia
| | - Julie A. Frearson
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - David W. Gray
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - Alan H. Fairlamb
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - Elizabeth A. Winzeler
- Department of PediatricsUniversity of California San Diego School of Medicine9500 Gilman Drive 0741La JollaCA92093USA
| | - David Waterson
- Medicines for Malaria VentureInternational Centre, Cointrin, Entrance G, 3rd FloorRoute de Pré-Bois 20, PO Box 1826Geneva1215Switzerland
| | - Simon F. Campbell
- Medicines for Malaria VentureInternational Centre, Cointrin, Entrance G, 3rd FloorRoute de Pré-Bois 20, PO Box 1826Geneva1215Switzerland
| | - Paul A. Willis
- Medicines for Malaria VentureInternational Centre, Cointrin, Entrance G, 3rd FloorRoute de Pré-Bois 20, PO Box 1826Geneva1215Switzerland
| | - Kevin D. Read
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| | - Ian H. Gilbert
- Drug Discovery UnitDivision of Biological Chemistry and Drug DiscoverySchool of Life SciencesUniversity of DundeeDundeeDD1 5EHUK
| |
Collapse
|
32
|
Skinner-Adams TS, Fisher GM, Riches AG, Hutt OE, Jarvis KE, Wilson T, von Itzstein M, Chopra P, Antonova-Koch Y, Meister S, Winzeler EA, Clarke M, Fidock DA, Burrows JN, Ryan JH, Andrews KT. Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone. Commun Biol 2019; 2:166. [PMID: 31069275 PMCID: PMC6499835 DOI: 10.1038/s42003-019-0397-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Accepted: 03/15/2019] [Indexed: 12/28/2022] Open
Abstract
Atovaquone-proguanil (Malarone®) is used for malaria prophylaxis and treatment. While the cytochrome bc1-inhibitor atovaquone has potent activity, proguanil's action is attributed to its cyclization-metabolite, cycloguanil. Evidence suggests that proguanil has limited intrinsic activity, associated with mitochondrial-function. Here we demonstrate that proguanil, and cyclization-blocked analogue tBuPG, have potent, but slow-acting, in vitro anti-plasmodial activity. Activity is folate-metabolism and isoprenoid biosynthesis-independent. In yeast dihydroorotate dehydrogenase-expressing parasites, proguanil and tBuPG slow-action remains, while bc1-inhibitor activity switches from comparatively fast to slow-acting. Like proguanil, tBuPG has activity against P. berghei liver-stage parasites. Both analogues act synergistically with bc1-inhibitors against blood-stages in vitro, however cycloguanil antagonizes activity. Together, these data suggest that proguanil is a potent slow-acting anti-plasmodial agent, that bc1 is essential to parasite survival independent of dihydroorotate dehydrogenase-activity, that Malarone® is a triple-drug combination that includes antagonistic partners and that a cyclization-blocked proguanil may be a superior combination partner for bc1-inhibitors in vivo.
Collapse
Affiliation(s)
- Tina S. Skinner-Adams
- Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111 Australia
| | - Gillian M. Fisher
- Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111 Australia
| | - Andrew G. Riches
- Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, VIC 3168 Australia
| | - Oliver E. Hutt
- Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, VIC 3168 Australia
| | - Karen E. Jarvis
- Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, VIC 3168 Australia
| | - Tony Wilson
- Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, VIC 3168 Australia
| | - Mark von Itzstein
- Institute for Glycomics, Griffith University Gold Coast Campus, Gold Coast, QLD 4222 Australia
| | - Pradeep Chopra
- Institute for Glycomics, Griffith University Gold Coast Campus, Gold Coast, QLD 4222 Australia
| | - Yevgeniya Antonova-Koch
- School of Medicine, University of California, San Diego, La Jolla, CA 92093 USA
- Present Address: California Institute for Biomedical Research (Calibr), La Jolla, CA 92037 USA
| | - Stephan Meister
- School of Medicine, University of California, San Diego, La Jolla, CA 92093 USA
- Present Address: Beckman Coulter Life Sciences in Indianapolis, Indianapolis, IN 46268 USA
| | | | - Mary Clarke
- Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111 Australia
| | - David A. Fidock
- Department of Microbiology and Immunology, and Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY 10032 USA
| | - Jeremy N. Burrows
- Medicines for Malaria Venture (MMV), Route de Pré Bois 20, Geneva, 1215 Switzerland
| | - John H. Ryan
- Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, VIC 3168 Australia
| | - Katherine T. Andrews
- Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111 Australia
| |
Collapse
|
33
|
Antonova-Koch Y, Meister S, Abraham M, Luth MR, Ottilie S, Lukens AK, Sakata-Kato T, Vanaerschot M, Owen E, Jado JC, Maher SP, Calla J, Plouffe D, Zhong Y, Chen K, Chaumeau V, Conway AJ, McNamara CW, Ibanez M, Gagaring K, Serrano FN, Eribez K, Taggard CM, Cheung AL, Lincoln C, Ambachew B, Rouillier M, Siegel D, Nosten F, Kyle DE, Gamo FJ, Zhou Y, Llinás M, Fidock DA, Wirth DF, Burrows J, Campo B, Winzeler EA. Open-source discovery of chemical leads for next-generation chemoprotective antimalarials. Science 2019; 362:362/6419/eaat9446. [PMID: 30523084 PMCID: PMC6516198 DOI: 10.1126/science.aat9446] [Citation(s) in RCA: 79] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Accepted: 10/18/2018] [Indexed: 11/19/2022]
Abstract
To discover leads for next-generation chemoprotective antimalarial drugs,we tested more than 500,000 compounds for their ability to inhibit liver-stage development of luciferase-expressing Plasmodium spp. parasites (681 compounds showed a half-maximal inhibitory concentration of less than 1micromolar).Cluster analysis identified potent and previously unreported scaffold families as well as other series previously associated with chemoprophylaxis. Further testing through multiple phenotypic assays that predict stage-specific and multispecies antimalarial activity distinguished compound classes that are likely to provide symptomatic relief by reducing asexual blood-stage parasitemia from those which are likely to only prevent malaria. Target identification by using functional assays, in vitro evolution, or metabolic profiling revealed 58 mitochondrial inhibitors but also many chemotypes possibly with previously unidentified mechanisms of action.
Collapse
Affiliation(s)
- Yevgeniya Antonova-Koch
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Stephan Meister
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Matthew Abraham
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Madeline R Luth
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Sabine Ottilie
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Amanda K Lukens
- Harvard T. H. Chan School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA.,The Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | | | - Manu Vanaerschot
- Division of Infectious Diseases, Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA
| | - Edward Owen
- Department of Biochemistry and Molecular Biology and Center for Malaria Research, Pennsylvania State University, University Park, PA 16802, USA
| | - Juan Carlos Jado
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Steven P Maher
- Center for Tropical and Emerging Global Diseases, University of Georgia, 500 D. W. Brooks Drive, Athens, GA 30602, USA.,Department of Global Health, University of South Florida, 3720 Spectrum Boulevard, Tampa, FL 33612, USA
| | - Jaeson Calla
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - David Plouffe
- The Genomics Institute of the Novartis Research Foundation, 10675 John J Hopkins Drive, San Diego, CA 92121, USA
| | - Yang Zhong
- The Genomics Institute of the Novartis Research Foundation, 10675 John J Hopkins Drive, San Diego, CA 92121, USA
| | - Kaisheng Chen
- The Genomics Institute of the Novartis Research Foundation, 10675 John J Hopkins Drive, San Diego, CA 92121, USA
| | - Victor Chaumeau
- Shoklo Malaria Research Unit, Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Amy J Conway
- Center for Tropical and Emerging Global Diseases, University of Georgia, 500 D. W. Brooks Drive, Athens, GA 30602, USA.,Department of Global Health, University of South Florida, 3720 Spectrum Boulevard, Tampa, FL 33612, USA
| | - Case W McNamara
- The Genomics Institute of the Novartis Research Foundation, 10675 John J Hopkins Drive, San Diego, CA 92121, USA
| | - Maureen Ibanez
- The Genomics Institute of the Novartis Research Foundation, 10675 John J Hopkins Drive, San Diego, CA 92121, USA
| | - Kerstin Gagaring
- The Genomics Institute of the Novartis Research Foundation, 10675 John J Hopkins Drive, San Diego, CA 92121, USA
| | - Fernando Neria Serrano
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos 28760, Madrid, Spain
| | - Korina Eribez
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Cullin McLean Taggard
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Andrea L Cheung
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Christie Lincoln
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Biniam Ambachew
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA
| | - Melanie Rouillier
- Medicines for Malaria Venture, Post Office Box 1826, 20 Route de Pre-Bois, 1215 Geneva 15, Switzerland
| | - Dionicio Siegel
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive 0741, La Jolla, CA 92093, USA
| | - François Nosten
- Shoklo Malaria Research Unit, Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Dennis E Kyle
- Center for Tropical and Emerging Global Diseases, University of Georgia, 500 D. W. Brooks Drive, Athens, GA 30602, USA.,Department of Global Health, University of South Florida, 3720 Spectrum Boulevard, Tampa, FL 33612, USA
| | - Francisco-Javier Gamo
- Medicines for Malaria Venture, Post Office Box 1826, 20 Route de Pre-Bois, 1215 Geneva 15, Switzerland
| | - Yingyao Zhou
- The Genomics Institute of the Novartis Research Foundation, 10675 John J Hopkins Drive, San Diego, CA 92121, USA
| | - Manuel Llinás
- Department of Biochemistry and Molecular Biology and Center for Malaria Research, Pennsylvania State University, University Park, PA 16802, USA.,Department of Chemistry and Center for Infectious Diseases Dynamics, Pennsylvania State University, University Park, PA 16802, USA
| | - David A Fidock
- Division of Infectious Diseases, Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA
| | - Dyann F Wirth
- Harvard T. H. Chan School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA.,The Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - Jeremy Burrows
- Medicines for Malaria Venture, Post Office Box 1826, 20 Route de Pre-Bois, 1215 Geneva 15, Switzerland
| | - Brice Campo
- Medicines for Malaria Venture, Post Office Box 1826, 20 Route de Pre-Bois, 1215 Geneva 15, Switzerland
| | - Elizabeth A Winzeler
- School of Medicine, University of California, San Diego, 9500 Gilman Drive 0760, La Jolla, CA 92093, USA. .,Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive 0741, La Jolla, CA 92093, USA
| |
Collapse
|
34
|
Leven M, Held J, Duffy S, Alves Avelar LA, Meister S, Delves M, Plouffe D, Kuna K, Tschan S, Avery VM, Winzeler EA, Mordmüller B, Kurz T. 8-Aminoquinolines with an Aminoxyalkyl Side Chain Exert in vitro Dual-Stage Antiplasmodial Activity. ChemMedChem 2019; 14:501-511. [PMID: 30605243 DOI: 10.1002/cmdc.201800691] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 12/13/2018] [Indexed: 12/29/2022]
Abstract
A series of novel 8-aminoquinolines (8-AQs) with an aminoxyalkyl side chain were synthesized and evaluated for in vitro antiplasmodial properties against asexual blood stages, liver stages, and sexual stages of Plasmodium falciparum. 8-AQs bearing 2-alkoxy and 5-phenoxy substituents on the quinoline ring system were found to be the most promising compounds under study, exhibiting potent blood schizontocidal and moderate tissue schizontocidal in vitro activity.
Collapse
Affiliation(s)
- Michael Leven
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstrasse 1, 40225, Düsseldorf, Germany
| | - Jana Held
- Institut für Tropenmedizin, Eberhard Karls Universität Tübingen, Wilhelmstrasse 27, 72074, Tübingen, Germany
| | - Sandra Duffy
- Eskitis Institute for Drug Discovery, Griffith University, Brisbane Innovation Park Campus, Nathan, QLD, 4111, Australia
| | - Leandro A Alves Avelar
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstrasse 1, 40225, Düsseldorf, Germany
| | - Stephan Meister
- Department of Pediatrics, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92037, USA
| | - Michael Delves
- Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK
| | - David Plouffe
- Genomics Institute of the Novartis Research Foundation Department, Novartis, 10675 John Jay Hopkins Drive, San Diego, CA, 92121, USA
| | - Krystina Kuna
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstrasse 1, 40225, Düsseldorf, Germany
| | - Serena Tschan
- Institut für Tropenmedizin, Eberhard Karls Universität Tübingen, Wilhelmstrasse 27, 72074, Tübingen, Germany
| | - Vicky M Avery
- Eskitis Institute for Drug Discovery, Griffith University, Brisbane Innovation Park Campus, Nathan, QLD, 4111, Australia
| | - Elizabeth A Winzeler
- Department of Pediatrics, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92037, USA
| | - Benjamin Mordmüller
- Institut für Tropenmedizin, Eberhard Karls Universität Tübingen, Wilhelmstrasse 27, 72074, Tübingen, Germany
| | - Thomas Kurz
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstrasse 1, 40225, Düsseldorf, Germany
| |
Collapse
|
35
|
Diedrich D, Stenzel K, Hesping E, Antonova-Koch Y, Gebru T, Duffy S, Fisher G, Schöler A, Meister S, Kurz T, Avery VM, Winzeler EA, Held J, Andrews KT, Hansen FK. One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites. Eur J Med Chem 2018; 158:801-813. [PMID: 30245402 PMCID: PMC6195125 DOI: 10.1016/j.ejmech.2018.09.018] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Revised: 09/05/2018] [Accepted: 09/06/2018] [Indexed: 12/30/2022]
Abstract
Malaria drug discovery has shifted from a focus on targeting asexual blood stage parasites, to the development of drugs that can also target exo-erythrocytic forms and/or gametocytes in order to prevent malaria and/or parasite transmission. In this work, we aimed to develop parasite-selective histone deacetylase inhibitors (HDACi) with activity against the disease-causing asexual blood stages of Plasmodium malaria parasites as well as with causal prophylactic and/or transmission blocking properties. An optimized one-pot, multi-component protocol via a sequential Ugi four-component reaction and hydroxylaminolysis was used for the preparation of a panel of peptoid-based HDACi. Several compounds displayed potent activity against drug-sensitive and drug-resistant P. falciparum asexual blood stages, high parasite-selectivity and submicromolar activity against exo-erythrocytic forms of P. berghei. Our optimization study resulted in the discovery of the hit compound 1u which combines high activity against asexual blood stage parasites (Pf 3D7 IC50: 4 nM; Pf Dd2 IC50: 1 nM) and P. berghei exo-erythrocytic forms (Pb EEF IC50: 25 nM) with promising parasite-specific activity (SIPf3D7/HepG2: 2496, SIPfDd2/HepG2: 9990, and SIPbEEF/HepG2: 400).
Collapse
Affiliation(s)
- Daniela Diedrich
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225, Düsseldorf, Germany
| | - Katharina Stenzel
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225, Düsseldorf, Germany; Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia
| | - Eva Hesping
- Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia
| | - Yevgeniya Antonova-Koch
- Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA, 92093, United States
| | - Tamirat Gebru
- Institut für Tropenmedizin, Eberhard Karls Universität Tübingen, Wilhelmstraße 27, 72074, Tübingen, Germany
| | - Sandra Duffy
- Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia
| | - Gillian Fisher
- Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia
| | - Andrea Schöler
- Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Medical Faculty, Leipzig University, Brüderstraße 34, 04103, Leipzig, Germany
| | - Stephan Meister
- Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA, 92093, United States
| | - Thomas Kurz
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225, Düsseldorf, Germany
| | - Vicky M Avery
- Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia
| | - Elizabeth A Winzeler
- Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA, 92093, United States
| | - Jana Held
- Institut für Tropenmedizin, Eberhard Karls Universität Tübingen, Wilhelmstraße 27, 72074, Tübingen, Germany
| | - Katherine T Andrews
- Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia.
| | - Finn K Hansen
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225, Düsseldorf, Germany; Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Medical Faculty, Leipzig University, Brüderstraße 34, 04103, Leipzig, Germany.
| |
Collapse
|
36
|
Orjuela-Sanchez P, Villa ZH, Moreno M, Tong-Rios C, Meister S, LaMonte GM, Campo B, Vinetz JM, Winzeler EA. Developing Plasmodium vivax Resources for Liver Stage Study in the Peruvian Amazon Region. ACS Infect Dis 2018. [PMID: 29542317 DOI: 10.1021/acsinfecdis.7b00198] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
To develop new drugs and vaccines for malaria elimination, it will be necessary to discover biological interventions, including small molecules that act against Plasmodium vivax exoerythrocytic forms. However, a robust in vitro culture system for P. vivax is still lacking. Thus, to study exoerythrocytic forms, researchers must have simultaneous access to fresh, temperature-controlled patient blood samples, as well as an anopheline mosquito colony. In addition, researchers must rely on native mosquito species to avoid introducing a potentially dangerous invasive species into a malaria-endemic region. Here, we report an in vitro culture system carried out on site in a malaria-endemic region for liver stage parasites of P. vivax sporozoites obtained from An. darlingi, the main malaria vector in the Americas. P. vivax sporozoites were obtained by dissection of salivary glands from infected An. darlingi mosquitoes and purified by Accudenz density gradient centrifugation. HC04 liver cells were exposed to P. vivax sporozoites and cultured up to 9 days. To overcome low P. vivax patient parasitemias, potentially lower mosquito vectorial capacity, and humid, nonsterile environmental conditions, a new antibiotic cocktail was included in tissue culture to prevent contamination. Culturing conditions supported exoerythrocytic (EEF) P. vivax liver stage growth up to 9 days and allowed for maturation into intrahepatocyte merosomes. Some of the identified small forms were resistant to atovaquone (1 μM) but sensitive to the phosphatidylinositol 4-kinase inhibitor, KDU691 (1 μM). This study reports a field-accessible EEF production process for drug discovery in a malaria-endemic site in which viable P. vivax sporozoites are used for drug studies using hepatocyte infection. Our data demonstrate that the development of meaningful, field-based resources for P. vivax liver stage drug screening and liver stage human malaria experimentation in the Amazon region is feasible.
Collapse
Affiliation(s)
- Pamela Orjuela-Sanchez
- Division of Host-Microbe Systems and Therapeutics, Health Sciences Center for Immunology, Infection and Inflammation, Department of Pediatrics, School of Medicine, University of California, San Diego, 9500 Gilman Drive #0760, La Jolla, California 92093-0760, United States
| | - Zaira Hellen Villa
- Laboratorio ICEMR-Amazonia, Laboratorios de Investigacion y Desarrollo, Facultad de Ciencias y Filosofia, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martín de Porres, Lima, 15102, Peru
| | - Marta Moreno
- Division of Infectious Diseases, Department of Medicine, University of California, San Diego, 9500 Gilman Drive #0760, La Jolla, California 92093-0760, United States
| | - Carlos Tong-Rios
- Laboratorio ICEMR-Amazonia, Laboratorios de Investigacion y Desarrollo, Facultad de Ciencias y Filosofia, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martín de Porres, Lima, 15102, Peru
| | - Stephan Meister
- Division of Host-Microbe Systems and Therapeutics, Health Sciences Center for Immunology, Infection and Inflammation, Department of Pediatrics, School of Medicine, University of California, San Diego, 9500 Gilman Drive #0760, La Jolla, California 92093-0760, United States
| | - Gregory M. LaMonte
- Division of Host-Microbe Systems and Therapeutics, Health Sciences Center for Immunology, Infection and Inflammation, Department of Pediatrics, School of Medicine, University of California, San Diego, 9500 Gilman Drive #0760, La Jolla, California 92093-0760, United States
| | - Brice Campo
- Medicines for Malaria Venture (MMV), International Center Cointrin, Block G, 20 Route de Pre-Bois, POB 1826, Geneva, CH-1215, Switzerland
| | - Joseph M. Vinetz
- Laboratorio ICEMR-Amazonia, Laboratorios de Investigacion y Desarrollo, Facultad de Ciencias y Filosofia, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martín de Porres, Lima, 15102, Peru
- Division of Infectious Diseases, Department of Medicine, University of California, San Diego, 9500 Gilman Drive #0760, La Jolla, California 92093-0760, United States
- Instituto de Medicina Tropical “Alexander von Humboldt”, Universidad Peruana Cayetano Heredia, Lima, 15102, Peru
| | - Elizabeth A. Winzeler
- Division of Host-Microbe Systems and Therapeutics, Health Sciences Center for Immunology, Infection and Inflammation, Department of Pediatrics, School of Medicine, University of California, San Diego, 9500 Gilman Drive #0760, La Jolla, California 92093-0760, United States
| |
Collapse
|
37
|
Stenzel K, Chua MJ, Duffy S, Antonova-Koch Y, Meister S, Hamacher A, Kassack MU, Winzeler E, Avery VM, Kurz T, Andrews KT, Hansen FK. Design and Synthesis of Terephthalic Acid-Based Histone Deacetylase Inhibitors with Dual-Stage Anti-Plasmodium Activity. ChemMedChem 2017; 12:1627-1636. [PMID: 28812327 DOI: 10.1002/cmdc.201700360] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Revised: 08/13/2017] [Indexed: 11/11/2022]
Abstract
In this work we aimed to develop parasite-selective histone deacetylase inhibitors (HDAC) inhibitors with activity against the disease-causing asexual blood stages of Plasmodium as well as causal prophylactic and/or transmission blocking properties. We report the design, synthesis, and biological testing of a series of 13 terephthalic acid-based HDAC inhibitors. All compounds showed low cytotoxicity against human embryonic kidney (HEK293) cells (IC50 : 8->51 μm), with 11 also having sub-micromolar in vitro activity against drug-sensitive (3D7) and multidrug-resistant (Dd2) asexual blood-stage P. falciparum parasites (IC50 ≈0.1-0.5 μm). A subset of compounds were examined for activity against early- and late-stage P. falciparum gametocytes and P. berghei exo-erythrocytic-stage parasites. While only moderate activity was observed against gametocytes (IC50 >2 μm), the most active compound (N1 -((3,5-dimethylbenzyl)oxy)-N4 -hydroxyterephthalamide, 1 f) showed sub-micromolar activity against P. berghei exo-erythrocytic stages (IC50 0.18 μm) and >270-fold better activity for exo-erythrocytic forms than for HepG2 cells. This, together with asexual-stage in vitro potency (IC50 ≈0.1 μm) and selectivity of this compound versus human cells (SI>450), suggests that 1 f may be a valuable starting point for the development of novel antimalarial drug leads with low host cell toxicity and multi-stage anti-plasmodial activity.
Collapse
Affiliation(s)
- Katharina Stenzel
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany.,Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia
| | - Ming Jang Chua
- Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia
| | - Sandra Duffy
- Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia
| | - Yevgeniya Antonova-Koch
- Department of Pediatrics, School of Medicine, University of California, San Diego, 9500 Gilman Drive 0741, La Jolla, CA, 92093, USA
| | - Stephan Meister
- Department of Pediatrics, School of Medicine, University of California, San Diego, 9500 Gilman Drive 0741, La Jolla, CA, 92093, USA
| | - Alexandra Hamacher
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany
| | - Matthias U Kassack
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany
| | - Elizabeth Winzeler
- Department of Pediatrics, School of Medicine, University of California, San Diego, 9500 Gilman Drive 0741, La Jolla, CA, 92093, USA
| | - Vicky M Avery
- Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia
| | - Thomas Kurz
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany
| | - Katherine T Andrews
- Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, QLD, 4111, Australia
| | - Finn K Hansen
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225, Düsseldorf, Germany.,Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Leipzig University, Brüderstraße 34, 04103, Leipzig, Germany
| |
Collapse
|
38
|
Leven M, Knaab TC, Held J, Duffy S, Meister S, Fischli C, Meitzner D, Lehmann U, Lungerich B, Kuna K, Stahlke P, Delves MJ, Buchholz M, Winzeler EA, Avery VM, Mordmüller B, Wittlin S, Kurz T. 3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally. J Med Chem 2017; 60:6036-6044. [PMID: 28653845 DOI: 10.1021/acs.jmedchem.7b00140] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Structural optimization of 3-hydroxy-N'-arylidenepropanehydrazonamides provided new analogs with nanomolar to subnanomolar antiplasmodial activity against asexual blood stages of Plasmodium falciparum, excellent parasite selectivity, and nanomolar activity against the earliest forms of gametocyte development. Particularly, derivatives with a 1,3-dihalo-6-trifluoromethylphenanthrene moiety showed outstanding in vivo properties and demonstrated in part curative activity in the Plasmodium berghei mouse model when administered perorally.
Collapse
Affiliation(s)
- Michael Leven
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf , Universitätsstraße 1, 40225 Düsseldorf, Germany
| | - Tanja C Knaab
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf , Universitätsstraße 1, 40225 Düsseldorf, Germany
| | - Jana Held
- Institut für Tropenmedizin, Eberhard Karls Universität Tübingen , Wilhelmstraße 27, 72074 Tübingen, Germany.,Centre de Recherches Medicales de Lambaréné , B.P.: 242 Lambaréné, Gabon
| | - Sandra Duffy
- Griffith Institute for Drug Discovery, Griffith University , Brisbane Innovation Park, Don Young Road, Nathan, Queensland 4111, Australia
| | - Stephan Meister
- Department of Pediatrics, School of Medicine, University of California, San Diego , La Jolla, California 92093, United States
| | - Christoph Fischli
- Swiss Tropical and Public Health Institute , Socinstraße 57, 4002 Basel, Switzerland.,University of Basel , CH-4003 Basel, Switzerland
| | - Diane Meitzner
- Department of Drug Design and Target Validation, Fraunhofer-Institut für Zelltherapie und Immunologie , Weinbergweg 22, 06120 Halle (Saale), Germany
| | - Ursula Lehmann
- Swiss Tropical and Public Health Institute , Socinstraße 57, 4002 Basel, Switzerland.,University of Basel , CH-4003 Basel, Switzerland
| | - Beate Lungerich
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf , Universitätsstraße 1, 40225 Düsseldorf, Germany
| | - Krystina Kuna
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf , Universitätsstraße 1, 40225 Düsseldorf, Germany
| | - Petra Stahlke
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf , Universitätsstraße 1, 40225 Düsseldorf, Germany
| | - Michael J Delves
- Cell and Molecular Biology, Department of Life Sciences, Imperial College , London SW7 2AZ, U.K
| | - Mirko Buchholz
- Department of Drug Design and Target Validation, Fraunhofer-Institut für Zelltherapie und Immunologie , Weinbergweg 22, 06120 Halle (Saale), Germany
| | - Elizabeth A Winzeler
- Department of Pediatrics, School of Medicine, University of California, San Diego , La Jolla, California 92093, United States
| | - Vicky M Avery
- Griffith Institute for Drug Discovery, Griffith University , Brisbane Innovation Park, Don Young Road, Nathan, Queensland 4111, Australia
| | - Benjamin Mordmüller
- Institut für Tropenmedizin, Eberhard Karls Universität Tübingen , Wilhelmstraße 27, 72074 Tübingen, Germany.,Centre de Recherches Medicales de Lambaréné , B.P.: 242 Lambaréné, Gabon
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute , Socinstraße 57, 4002 Basel, Switzerland.,University of Basel , CH-4003 Basel, Switzerland
| | - Thomas Kurz
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf , Universitätsstraße 1, 40225 Düsseldorf, Germany
| |
Collapse
|
39
|
Magistrado PA, Corey VC, Lukens AK, LaMonte G, Sasaki E, Meister S, Wree M, Winzeler E, Wirth DF. Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes. ACS Infect Dis 2016; 2:816-826. [PMID: 27933786 PMCID: PMC5109296 DOI: 10.1021/acsinfecdis.6b00025] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
![]()
MMV007564
is a novel antimalarial benzimidazolyl piperidine chemotype
identified in cellular screens. To identify the genetic determinant
of MMV007564 resistance, parasites were cultured in the presence of
the compound to generate resistant lines. Whole genome sequencing
revealed distinct mutations in the gene named Plasmodium
falciparum cyclic amine resistance locus (pfcarl), encoding a conserved protein of unknown function.
Mutations in pfcarl are strongly associated with
resistance to a structurally unrelated class of compounds, the imidazolopiperazines,
including KAF156, currently in clinical trials. Our data demonstrate
that pfcarl mutations confer resistance to two distinct
compound classes, benzimidazolyl piperidines and imidazolopiperazines.
However, MMV007564 and the imidazolopiperazines, KAF156 and GNF179,
have different timings of action in the asexual blood stage and different
potencies against the liver and sexual blood stages. These data suggest
that pfcarl is a multidrug-resistance gene rather
than a common target for benzimidazolyl piperidines and imidazolopiperazines.
Collapse
Affiliation(s)
- Pamela A. Magistrado
- Department
of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 02115, United States
| | - Victoria C. Corey
- School
of Medicine, University of California—San Diego, La Jolla, California 92093, United States
| | - Amanda K. Lukens
- Department
of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 02115, United States
- Infectious
Disease Program, The Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, United States
| | - Greg LaMonte
- School
of Medicine, University of California—San Diego, La Jolla, California 92093, United States
| | - Erika Sasaki
- School
of Medicine, University of California—San Diego, La Jolla, California 92093, United States
| | - Stephan Meister
- School
of Medicine, University of California—San Diego, La Jolla, California 92093, United States
| | - Melanie Wree
- School
of Medicine, University of California—San Diego, La Jolla, California 92093, United States
| | - Elizabeth Winzeler
- School
of Medicine, University of California—San Diego, La Jolla, California 92093, United States
| | - Dyann F. Wirth
- Department
of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 02115, United States
- Infectious
Disease Program, The Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
40
|
Patejdl R, Winkelmann A, Ehler J, Zettl H, Meister S, Zettl UK. [Diagnostic Workup and Treatment of Antibody-Related Encephalomyelitis]. Fortschr Neurol Psychiatr 2016; 84:S88-S91. [PMID: 27806422 DOI: 10.1055/s-0042-113963] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
The results of laboratory tests for antineuronal antibodies in immune-mediated encephalitis nowadays are not only relevant for diagnostic purposes but are instead closely connected to outcome measures and treatment response. Besides the mere detection of antibodies, investigating the cerebrospinal fluid is indispensible to rule out an infectious etiology of encephalitis prior to the initiation of immunosuppressive treatment, whereas imaging studies are relevant to gain information on the temporal course of disease and for ruling out other etiologies, e. g. hippocampal gliomas. This work gives an overview on the clinical course and findings of laboratory, electroencephalography (EEG) and imaging studies in relevant types of autoimmune mediated encephalitis. Furthermore, it gives a synopsis on contemporary treatment strategies.
Collapse
Affiliation(s)
- R Patejdl
- Institut für Physiologie, Universitätsmedizin Rostock
| | - A Winkelmann
- Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock
| | - J Ehler
- Klinik für Anästhesiologie und Intensivtherapie, Universitätsmedizin Rostock
| | - H Zettl
- Tumorzentrum, Universitätsmedizin Rostock
| | - S Meister
- Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock
| | - U K Zettl
- Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock
| |
Collapse
|
41
|
Le Manach C, Nchinda AT, Paquet T, Gonzàlez Cabrera D, Younis Y, Han Z, Bashyam S, Zabiulla M, Taylor D, Lawrence N, White KL, Charman SA, Waterson D, Witty MJ, Wittlin S, Botha ME, Nondaba SH, Reader J, Birkholtz LM, Jiménez-Díaz MB, Martínez MS, Ferrer S, Angulo-Barturen I, Meister S, Antonova-Koch Y, Winzeler EA, Street LJ, Chibale K. Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle. J Med Chem 2016; 59:9890-9905. [PMID: 27748596 DOI: 10.1021/acs.jmedchem.6b01265] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Introduction of water-solubilizing groups on the 5-phenyl ring of a 2-aminopyrazine series led to the identification of highly potent compounds against the blood life-cycle stage of the human malaria parasite Plasmodium falciparum. Several compounds displayed high in vivo efficacy in two different mouse models for malaria, P. berghei-infected mice and P. falciparum-infected NOD-scid IL-2Rγnull mice. One of the frontrunners, compound 3, was identified to also have good pharmacokinetics and additionally very potent activity against the liver and gametocyte parasite life-cycle stages.
Collapse
Affiliation(s)
- Claire Le Manach
- Drug Discovery and Development Center (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Aloysius T Nchinda
- Drug Discovery and Development Center (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Tanya Paquet
- Drug Discovery and Development Center (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Diego Gonzàlez Cabrera
- Drug Discovery and Development Center (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Yassir Younis
- Drug Discovery and Development Center (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Ze Han
- Drug Discovery and Development Center (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Sridevi Bashyam
- Syngene International Ltd. , Biocon Park, Plot No. 2 & 3, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India
| | - Mohammed Zabiulla
- Syngene International Ltd. , Biocon Park, Plot No. 2 & 3, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India
| | - Dale Taylor
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Observatory, Cape Town, 7925, South Africa
| | - Nina Lawrence
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Observatory, Cape Town, 7925, South Africa
| | - Karen L White
- Centre for Drug Candidate Optimisation, Monash University , 381 Royal Parade, Parkville, Victoria 3052 Australia
| | - Susan A Charman
- Centre for Drug Candidate Optimisation, Monash University , 381 Royal Parade, Parkville, Victoria 3052 Australia
| | - David Waterson
- Medicines for Malaria Venture , ICC, Route de Pré-Bois 20, P.O. Box 1826, 1215 Geneva, Switzerland
| | - Michael J Witty
- Medicines for Malaria Venture , ICC, Route de Pré-Bois 20, P.O. Box 1826, 1215 Geneva, Switzerland
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute , Socinstrasse 57, 4002 Basel, Switzerland.,University of Basel , 4003 Basel, Switzerland
| | - Mariëtte E Botha
- Department of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria , Private Bag X20, Hatfield 0028, South Africa
| | - Sindisiswe H Nondaba
- Department of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria , Private Bag X20, Hatfield 0028, South Africa
| | - Janette Reader
- Department of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria , Private Bag X20, Hatfield 0028, South Africa
| | - Lyn-Marie Birkholtz
- Department of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria , Private Bag X20, Hatfield 0028, South Africa
| | - María Belén Jiménez-Díaz
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain
| | - María Santos Martínez
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain
| | - Santiago Ferrer
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain
| | - Iñigo Angulo-Barturen
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain
| | - Stephan Meister
- Department of Pediatrics, Pharmacology and Drug Discovery, School of Medicine, University of California, San Diego (UCSD) , 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Yevgeniya Antonova-Koch
- Department of Pediatrics, Pharmacology and Drug Discovery, School of Medicine, University of California, San Diego (UCSD) , 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Elizabeth A Winzeler
- Department of Pediatrics, Pharmacology and Drug Discovery, School of Medicine, University of California, San Diego (UCSD) , 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Leslie J Street
- Drug Discovery and Development Center (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa
| | - Kelly Chibale
- Drug Discovery and Development Center (H3D), Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa.,South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Rondebosch 7701, South Africa
| |
Collapse
|
42
|
Williamson AE, Ylioja PM, Robertson MN, Antonova-Koch Y, Avery V, Baell JB, Batchu H, Batra S, Burrows JN, Bhattacharyya S, Calderon F, Charman SA, Clark J, Crespo B, Dean M, Debbert SL, Delves M, Dennis ASM, Deroose F, Duffy S, Fletcher S, Giaever G, Hallyburton I, Gamo FJ, Gebbia M, Guy RK, Hungerford Z, Kirk K, Lafuente-Monasterio M, Lee A, Meister S, Nislow C, Overington JP, Papadatos G, Patiny L, Pham J, Ralph S, Ruecker A, Ryan E, Southan C, Srivastava K, Swain C, Tarnowski M, Thomson P, Turner P, Wallace IM, Wells TC, White K, White L, Willis P, Winzeler EA, Wittlin S, Todd MH. Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. ACS Cent Sci 2016; 2:687-701. [PMID: 27800551 PMCID: PMC5084075 DOI: 10.1021/acscentsci.6b00086] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Indexed: 05/26/2023]
Abstract
The development of new antimalarial compounds remains a pivotal part of the strategy for malaria elimination. Recent large-scale phenotypic screens have provided a wealth of potential starting points for hit-to-lead campaigns. One such public set is explored, employing an open source research mechanism in which all data and ideas were shared in real time, anyone was able to participate, and patents were not sought. One chemical subseries was found to exhibit oral activity but contained a labile ester that could not be replaced without loss of activity, and the original hit exhibited remarkable sensitivity to minor structural change. A second subseries displayed high potency, including activity within gametocyte and liver stage assays, but at the cost of low solubility. As an open source research project, unexplored avenues are clearly identified and may be explored further by the community; new findings may be cumulatively added to the present work.
Collapse
Affiliation(s)
- Alice E. Williamson
- School
of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Paul M. Ylioja
- School
of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Murray N. Robertson
- School
of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Yevgeniya Antonova-Koch
- Department
of Pediatrics, Pharmacology & Drug Development, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Vicky Avery
- Discovery Biology, Eskitis Institute for
Drug Discovery, Griffith University, Nathan, Queensland 4111, Australia
| | - Jonathan B. Baell
- Monash
Institute of Pharmaceutical Sciences, Monash
University, 381 Royal
Parade, Parkville, Victoria 3052, Australia
| | - Harikrishna Batchu
- CSIR-Central
Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226 031, India
| | - Sanjay Batra
- CSIR-Central
Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226 031, India
| | - Jeremy N. Burrows
- Medicines for Malaria Venture, PO Box
1826, 20 rte de Pre-Bois, 1215 Geneva 15, Switzerland
| | - Soumya Bhattacharyya
- CSIR-Central
Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226 031, India
| | - Felix Calderon
- Tres Cantos Medicines Development Campus, Diseases of the Developing
World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Susan A. Charman
- Monash
Institute of Pharmaceutical Sciences, Monash
University, 381 Royal
Parade, Parkville, Victoria 3052, Australia
| | - Julie Clark
- Department of Chemical
Biology & Therapeutics, St. Jude Children’s
Research Hospital, MS 1000, Room E9050, 262 Danny Thomas Place, Memphis, Tennessee 38105-3678, United States
| | - Benigno Crespo
- Tres Cantos Medicines Development Campus, Diseases of the Developing
World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Matin Dean
- School
of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Stefan L. Debbert
- Department of Chemistry, Lawrence University, 233 Steitz Science
Hall, 711 East Boldt Way, Appleton, Wisconsin 54911, United States
| | - Michael Delves
- Department of Life Sciences, Imperial College London, South Kensington, London SW7 2AZ, U.K.
| | - Adelaide S. M. Dennis
- Research School of Biology, The Australian National University, Canberra, ACT 2601, Australia
| | - Frederik Deroose
- Asclepia Outsourcing Solutions, Damvalleistraat 49, B-9070 Destelbergen, Belgium
| | - Sandra Duffy
- Discovery Biology, Eskitis Institute for
Drug Discovery, Griffith University, Nathan, Queensland 4111, Australia
| | - Sabine Fletcher
- Discovery Biology, Eskitis Institute for
Drug Discovery, Griffith University, Nathan, Queensland 4111, Australia
| | - Guri Giaever
- Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, Ontario M5S 3E1, Canada
| | - Irene Hallyburton
- Drug Discovery Unit, Division of Biological
Chemistry and Drug Discovery, University
of Dundee, Dundee, DD1 5EH, U.K.
| | - Francisco-Javier Gamo
- Tres Cantos Medicines Development Campus, Diseases of the Developing
World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Marinella Gebbia
- Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, Ontario M5S 3E1, Canada
| | - R. Kiplin Guy
- Department of Chemical
Biology & Therapeutics, St. Jude Children’s
Research Hospital, MS 1000, Room E9050, 262 Danny Thomas Place, Memphis, Tennessee 38105-3678, United States
| | - Zoe Hungerford
- School
of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Kiaran Kirk
- Research School of Biology, The Australian National University, Canberra, ACT 2601, Australia
| | - Maria
J. Lafuente-Monasterio
- Tres Cantos Medicines Development Campus, Diseases of the Developing
World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Anna Lee
- Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, Ontario M5S 3E1, Canada
| | - Stephan Meister
- Department
of Pediatrics, Pharmacology & Drug Development, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Corey Nislow
- Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, Ontario M5S 3E1, Canada
| | - John P. Overington
- European Molecular
Biology Laboratory—European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SD, U.K.
| | - George Papadatos
- European Molecular
Biology Laboratory—European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SD, U.K.
| | - Luc Patiny
- Institute of Chemical Sciences and Engineering
(ISIC), Ecole Polytechnique Fédérale
de Lausanne (EPFL), Lausanne 1015, Switzerland
| | - James Pham
- Department
of Biochemistry & Molecular Biology, Bio21 Molecular Science and
Biotechnology Institute, The University
of Melbourne, Melbourne, Victoria 3010, Australia
| | - Stuart
A. Ralph
- Department
of Biochemistry & Molecular Biology, Bio21 Molecular Science and
Biotechnology Institute, The University
of Melbourne, Melbourne, Victoria 3010, Australia
| | - Andrea Ruecker
- Department of Life Sciences, Imperial College London, South Kensington, London SW7 2AZ, U.K.
| | - Eileen Ryan
- Monash
Institute of Pharmaceutical Sciences, Monash
University, 381 Royal
Parade, Parkville, Victoria 3052, Australia
| | - Christopher Southan
- IUPHAR/BPS Guide to PHARMACOLOGY, Centre for Integrative Physiology,
School of Biomedical Sciences, University
of Edinburgh, Edinburgh, EH8 9XD, U.K.
| | - Kumkum Srivastava
- CSIR-Central
Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226 031, India
| | - Chris Swain
- Cambridge MedChem
Consulting, 8 Mangers
Lane, Duxford, Cambridge CB22 4RN, U.K.
| | - Matthew
J. Tarnowski
- School
of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Patrick Thomson
- School
of Chemistry, The University of Edinburgh, Joseph Black Building, West Mains
Road, Edinburgh EH9 3JJ, U.K.
| | - Peter Turner
- School
of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Iain M. Wallace
- European Molecular
Biology Laboratory—European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SD, U.K.
| | - Timothy
N. C. Wells
- Medicines for Malaria Venture, PO Box
1826, 20 rte de Pre-Bois, 1215 Geneva 15, Switzerland
| | - Karen White
- Monash
Institute of Pharmaceutical Sciences, Monash
University, 381 Royal
Parade, Parkville, Victoria 3052, Australia
| | - Laura White
- School
of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Paul Willis
- Medicines for Malaria Venture, PO Box
1826, 20 rte de Pre-Bois, 1215 Geneva 15, Switzerland
| | - Elizabeth A. Winzeler
- Department
of Pediatrics, Pharmacology & Drug Development, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051 Basel, Switzerland
| | - Matthew H. Todd
- School
of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| |
Collapse
|
43
|
Baragaña B, Norcross NR, Wilson C, Porzelle A, Hallyburton I, Grimaldi R, Osuna-Cabello M, Norval S, Riley J, Stojanovski L, Simeons FRC, Wyatt PG, Delves MJ, Meister S, Duffy S, Avery VM, Winzeler EA, Sinden RE, Wittlin S, Frearson JA, Gray DW, Fairlamb AH, Waterson D, Campbell SF, Willis P, Read KD, Gilbert IH. Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. J Med Chem 2016; 59:9672-9685. [PMID: 27631715 PMCID: PMC5108032 DOI: 10.1021/acs.jmedchem.6b00723] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
![]()
The antiplasmodial activity, DMPK
properties, and efficacy of a series of quinoline-4-carboxamides are
described. This series was identified from a phenotypic screen against
the blood stage of Plasmodium falciparum (3D7) and
displayed moderate potency but with suboptimal physicochemical properties
and poor microsomal stability. The screening hit (1,
EC50 = 120 nM) was optimized to lead molecules with low
nanomolar in vitro potency. Improvement of the pharmacokinetic profile
led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED90 values
below 1 mg/kg when dosed orally for 4 days. The favorable potency,
selectivity, DMPK properties, and efficacy coupled with a novel mechanism
of action, inhibition of translation elongation factor 2 (PfEF2), led to progression of 2 (DDD107498)
to preclinical development.
Collapse
Affiliation(s)
- Beatriz Baragaña
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Neil R Norcross
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Caroline Wilson
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Achim Porzelle
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Irene Hallyburton
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Raffaella Grimaldi
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Maria Osuna-Cabello
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Suzanne Norval
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Jennifer Riley
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Laste Stojanovski
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Frederick R C Simeons
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Paul G Wyatt
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Michael J Delves
- Cell and Molecular Biology, Department of Life Sciences, Imperial College , London, SW7 2AZ, U.K
| | - Stephan Meister
- School of Medicine, University of California, San Diego , 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Sandra Duffy
- Eskitis Institute, Griffith University , Brisbane Innovation Park, Nathan Campus, Brisbane, QLD 4111, Australia
| | - Vicky M Avery
- Eskitis Institute, Griffith University , Brisbane Innovation Park, Nathan Campus, Brisbane, QLD 4111, Australia
| | - Elizabeth A Winzeler
- School of Medicine, University of California, San Diego , 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Robert E Sinden
- Cell and Molecular Biology, Department of Life Sciences, Imperial College , London, SW7 2AZ, U.K
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute, Swiss TPH, Socinstrasse 57, 4051 Basel, Switzerland.,University of Basel , CH-4003 Basel, Switzerland
| | - Julie A Frearson
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - David W Gray
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Alan H Fairlamb
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - David Waterson
- Medicines for Malaria Venture , International Centre Cointrin, Entrance G, 3rd Floor, Route de Pré-Bois 20, P.O. Box 1826, CH-1215, Geneva 15, Switzerland
| | - Simon F Campbell
- Medicines for Malaria Venture , International Centre Cointrin, Entrance G, 3rd Floor, Route de Pré-Bois 20, P.O. Box 1826, CH-1215, Geneva 15, Switzerland
| | - Paul Willis
- Medicines for Malaria Venture , International Centre Cointrin, Entrance G, 3rd Floor, Route de Pré-Bois 20, P.O. Box 1826, CH-1215, Geneva 15, Switzerland
| | - Kevin D Read
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Ian H Gilbert
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| |
Collapse
|
44
|
Norcross NR, Baragaña B, Wilson C, Hallyburton I, Osuna-Cabello M, Norval S, Riley J, Stojanovski L, Simeons FRC, Porzelle A, Grimaldi R, Wittlin S, Duffy S, Avery VM, Meister S, Sanz L, Jiménez-Díaz B, Angulo-Barturen I, Ferrer S, Martínez MS, Gamo FJ, Frearson JA, Gray DW, Fairlamb AH, Winzeler EA, Waterson D, Campbell SF, Willis P, Read KD, Gilbert IH. Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. J Med Chem 2016; 59:6101-20. [PMID: 27314305 PMCID: PMC4947981 DOI: 10.1021/acs.jmedchem.6b00028] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
![]()
In this paper we describe the optimization
of a phenotypic hit
against Plasmodium falciparum, based on a trisubstituted
pyrimidine scaffold. This led to compounds with good pharmacokinetics
and oral activity in a P. berghei mouse model of
malaria. The most promising compound (13) showed a reduction
in parasitemia of 96% when dosed at 30 mg/kg orally once a day for
4 days in the P. berghei mouse model of malaria.
It also demonstrated a rapid rate of clearance of the erythrocytic
stage of P. falciparum in the SCID mouse model with
an ED90 of 11.7 mg/kg when dosed orally. Unfortunately,
the compound is a potent inhibitor of cytochrome P450 enzymes, probably
due to a 4-pyridyl substituent. Nevertheless, this is a lead molecule
with a potentially useful antimalarial profile, which could either
be further optimized or be used for target hunting.
Collapse
Affiliation(s)
- Neil R Norcross
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Beatriz Baragaña
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Caroline Wilson
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Irene Hallyburton
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Maria Osuna-Cabello
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Suzanne Norval
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Jennifer Riley
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Laste Stojanovski
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Frederick R C Simeons
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Achim Porzelle
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Raffaella Grimaldi
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute (Swiss TPH) , Socinstrasse 57, 4051 Basel, Switzerland.,University of Basel , CH-4003 Basel, Switzerland
| | - Sandra Duffy
- Discovery Biology, Eskitis Institute for Drug Discovery, Griffith University , Nathan, Queensland 4111, Australia
| | - Vicky M Avery
- Discovery Biology, Eskitis Institute for Drug Discovery, Griffith University , Nathan, Queensland 4111, Australia
| | - Stephan Meister
- Department of Pediatrics, University of California, San Diego School of Medicine , 9500 Gilman Drive, 0741, La Jolla, California 92093, United States
| | - Laura Sanz
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - Belén Jiménez-Díaz
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - Iñigo Angulo-Barturen
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - Santiago Ferrer
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - María Santos Martínez
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - Francisco Javier Gamo
- Diseases of the Developing World-Tres Cantos Medicines Development Campus, GlaxoSmithKline , c/Severo Ochoa, 2, Tres Cantos, 28760, Madrid, Spain
| | - Julie A Frearson
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - David W Gray
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Alan H Fairlamb
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Elizabeth A Winzeler
- Department of Pediatrics, University of California, San Diego School of Medicine , 9500 Gilman Drive, 0741, La Jolla, California 92093, United States
| | - David Waterson
- Medicines for Malaria Venture , International Center Cointrin, Entrance G, 3rd Floor, Route de Pré-Bois 20, P.O. Box 1826, CH-1215, Geneva 15, Switzerland
| | - Simon F Campbell
- Medicines for Malaria Venture , International Center Cointrin, Entrance G, 3rd Floor, Route de Pré-Bois 20, P.O. Box 1826, CH-1215, Geneva 15, Switzerland
| | - Paul Willis
- Medicines for Malaria Venture , International Center Cointrin, Entrance G, 3rd Floor, Route de Pré-Bois 20, P.O. Box 1826, CH-1215, Geneva 15, Switzerland
| | - Kevin D Read
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| | - Ian H Gilbert
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dundee, DD1 5EH, U.K
| |
Collapse
|
45
|
Corey VC, Lukens AK, Istvan ES, Lee MCS, Franco V, Magistrado P, Coburn-Flynn O, Sakata-Kato T, Fuchs O, Gnädig NF, Goldgof G, Linares M, Gomez-Lorenzo MG, De Cózar C, Lafuente-Monasterio MJ, Prats S, Meister S, Tanaseichuk O, Wree M, Zhou Y, Willis PA, Gamo FJ, Goldberg DE, Fidock DA, Wirth DF, Winzeler EA. A broad analysis of resistance development in the malaria parasite. Nat Commun 2016; 7:11901. [PMID: 27301419 PMCID: PMC4912613 DOI: 10.1038/ncomms11901] [Citation(s) in RCA: 85] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2015] [Accepted: 05/10/2016] [Indexed: 01/25/2023] Open
Abstract
Microbial resistance to chemotherapy has caused countless deaths where malaria is endemic. Chemotherapy may fail either due to pre-existing resistance or evolution of drug-resistant parasites. Here we use a diverse set of antimalarial compounds to investigate the acquisition of drug resistance and the degree of cross-resistance against common resistance alleles. We assess cross-resistance using a set of 15 parasite lines carrying resistance-conferring alleles in pfatp4, cytochrome bc1, pfcarl, pfdhod, pfcrt, pfmdr, pfdhfr, cytoplasmic prolyl t-RNA synthetase or hsp90. Subsequently, we assess whether resistant parasites can be obtained after several rounds of drug selection. Twenty-three of the 48 in vitro selections result in resistant parasites, with time to resistance onset ranging from 15 to 300 days. Our data indicate that pre-existing resistance may not be a major hurdle for novel-target antimalarial candidates, and focusing our attention on fast-killing compounds may result in a slower onset of clinical resistance. It is unclear whether new antimalarial compounds may rapidly lose effectiveness in the field because of parasite resistance. Here, Corey et al. investigate the acquisition of drug resistance and the extent to which common resistance mechanisms decrease susceptibility to a diverse set of 50 antimalarial compounds.
Collapse
Affiliation(s)
- Victoria C Corey
- Department of Pediatrics, School of Medicine, University of California San Diego, 9500 Gilman Drive 0741, La Jolla, California 92093, USA
| | - Amanda K Lukens
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115, USA.,Infectious Disease Program, The Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, USA
| | - Eva S Istvan
- Department of Medicine and Microbiology, Washington University School of Medicine, St Louis, Missouri 63110, USA
| | - Marcus C S Lee
- Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
| | - Virginia Franco
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain
| | - Pamela Magistrado
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115, USA
| | - Olivia Coburn-Flynn
- Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
| | - Tomoyo Sakata-Kato
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115, USA
| | - Olivia Fuchs
- Department of Pediatrics, School of Medicine, University of California San Diego, 9500 Gilman Drive 0741, La Jolla, California 92093, USA
| | - Nina F Gnädig
- Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
| | - Greg Goldgof
- Department of Pediatrics, School of Medicine, University of California San Diego, 9500 Gilman Drive 0741, La Jolla, California 92093, USA
| | - Maria Linares
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain
| | - Maria G Gomez-Lorenzo
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain
| | - Cristina De Cózar
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain
| | - Maria Jose Lafuente-Monasterio
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain
| | - Sara Prats
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain
| | - Stephan Meister
- Department of Pediatrics, School of Medicine, University of California San Diego, 9500 Gilman Drive 0741, La Jolla, California 92093, USA
| | - Olga Tanaseichuk
- The Genomics Institute of the Novartis Research Foundation, 10675 John J Hopkins Drive, San Diego, California 92121, USA
| | - Melanie Wree
- Department of Pediatrics, School of Medicine, University of California San Diego, 9500 Gilman Drive 0741, La Jolla, California 92093, USA
| | - Yingyao Zhou
- The Genomics Institute of the Novartis Research Foundation, 10675 John J Hopkins Drive, San Diego, California 92121, USA
| | - Paul A Willis
- Medicines for Malaria Venture, PO Box 1826, 20 route de Pre-Bois, 1215 Geneva 15, Switzerland
| | - Francisco-Javier Gamo
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain
| | - Daniel E Goldberg
- Department of Medicine and Microbiology, Washington University School of Medicine, St Louis, Missouri 63110, USA
| | - David A Fidock
- Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
| | - Dyann F Wirth
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115, USA.,Infectious Disease Program, The Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, USA
| | - Elizabeth A Winzeler
- Department of Pediatrics, School of Medicine, University of California San Diego, 9500 Gilman Drive 0741, La Jolla, California 92093, USA
| |
Collapse
|
46
|
Lu HH, Pronin SV, Antonova-Koch Y, Meister S, Winzeler EA, Shenvi RA. Synthesis of (+)-7,20-Diisocyanoadociane and Liver-Stage Antiplasmodial Activity of the Isocyanoterpene Class. J Am Chem Soc 2016; 138:7268-71. [PMID: 27244042 DOI: 10.1021/jacs.6b03899] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
7,20-Diisocyanoadociane, a scarce marine metabolite with potent antimalarial activity, was synthesized as a single enantiomer in 13 steps from simple building blocks (17 linear steps). Chemical synthesis enabled identification of isocyanoterpene antiplasmodial activity against liver-stage parasites, which suggested that inhibition of heme detoxification does not exclusively underlie the mechanism of action of this class.
Collapse
Affiliation(s)
- Hai-Hua Lu
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Sergey V Pronin
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Yevgeniya Antonova-Koch
- Department of Pediatrics, University of California, San Diego, School of Medicine , 9500 Gilman Drive 0741, La Jolla, California 92093, United States
| | - Stephan Meister
- Department of Pediatrics, University of California, San Diego, School of Medicine , 9500 Gilman Drive 0741, La Jolla, California 92093, United States
| | - Elizabeth A Winzeler
- Department of Pediatrics, University of California, San Diego, School of Medicine , 9500 Gilman Drive 0741, La Jolla, California 92093, United States
| | - Ryan A Shenvi
- Department of Chemistry, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| |
Collapse
|
47
|
Swann J, Corey V, Scherer CA, Kato N, Comer E, Maetani M, Antonova-Koch Y, Reimer C, Gagaring K, Ibanez M, Plouffe D, Zeeman AM, Kocken CHM, McNamara CW, Schreiber SL, Campo B, Winzeler EA, Meister S. High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria. ACS Infect Dis 2016; 2:281-293. [PMID: 27275010 PMCID: PMC4890880 DOI: 10.1021/acsinfecdis.5b00143] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2015] [Indexed: 11/29/2022]
Abstract
In order to identify the most attractive starting points for drugs that can be used to prevent malaria, a diverse chemical space comprising tens of thousands to millions of small molecules may need to be examined. Achieving this throughput necessitates the development of efficient ultra-high-throughput screening methods. Here, we report the development and evaluation of a luciferase-based phenotypic screen of malaria exoerythrocytic-stage parasites optimized for a 1536-well format. This assay uses the exoerythrocytic stage of the rodent malaria parasite, Plasmodium berghei, and a human hepatoma cell line. We use this assay to evaluate several biased and unbiased compound libraries, including two small sets of molecules (400 and 89 compounds, respectively) with known activity against malaria erythrocytic-stage parasites and a set of 9886 diversity-oriented synthesis (DOS)-derived compounds. Of the compounds screened, we obtain hit rates of 12-13 and 0.6% in preselected and naïve libraries, respectively, and identify 52 compounds with exoerythrocytic-stage activity less than 1 μM and having minimal host cell toxicity. Our data demonstrate the ability of this method to identify compounds known to have causal prophylactic activity in both human and animal models of malaria, as well as novel compounds, including some exclusively active against parasite exoerythrocytic stages.
Collapse
Affiliation(s)
- Justine Swann
- School of Medicine, Department of Pediatrics, Pharmacology & Drug Discovery, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Victoria Corey
- School of Medicine, Department of Pediatrics, Pharmacology & Drug Discovery, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Christina A. Scherer
- The Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, United States
| | - Nobutaka Kato
- The Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, United States
| | - Eamon Comer
- The Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, United States
| | - Micah Maetani
- The Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, United States
| | - Yevgeniya Antonova-Koch
- School of Medicine, Department of Pediatrics, Pharmacology & Drug Discovery, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Christin Reimer
- School of Medicine, Department of Pediatrics, Pharmacology & Drug Discovery, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Kerstin Gagaring
- Genomics Institute of the Novartis Research Foundation (GNF), 10675
John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Maureen Ibanez
- Genomics Institute of the Novartis Research Foundation (GNF), 10675
John Jay Hopkins Drive, San Diego, California 92121, United States
| | - David Plouffe
- Genomics Institute of the Novartis Research Foundation (GNF), 10675
John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Anne-Marie Zeeman
- Department of Parasitology, Biomedical Primate Research Centre, P.O. Box 3306, 2280 GH Rijswijk, The Netherlands
| | - Clemens H. M. Kocken
- Department of Parasitology, Biomedical Primate Research Centre, P.O. Box 3306, 2280 GH Rijswijk, The Netherlands
| | - Case W. McNamara
- The Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, United States
| | - Stuart L. Schreiber
- The Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, United States
| | - Brice Campo
- Medicines for Malaria Venture (MMV), Meyrin 2015, Switzerland
| | - Elizabeth A. Winzeler
- School of Medicine, Department of Pediatrics, Pharmacology & Drug Discovery, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Stephan Meister
- School of Medicine, Department of Pediatrics, Pharmacology & Drug Discovery, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| |
Collapse
|
48
|
Mittag N, Meister S, Berg AMJ, Walther UI. A Case Report of a Carbamazepine Overdose With Focus on Pharmacokinetic Aspects. Pharmacopsychiatry 2016; 49:76-8. [PMID: 26797932 DOI: 10.1055/s-0035-1569268] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
In this article a case of carbamazepine overdose is reported. It is common to use immuno-based methods in the field of therapeutic drug monitoring but it might be difficult to adapt such values to toxicological cases. For carbamazepine overdoses it is recommended also to determine the metabolite carbamazepine-10,11-epoxide. Especially for critical conditions a definite substance identification should be performed. In addition, quantifying main metabolites is recommended for an acute clinical toxicological assessment.
Collapse
Affiliation(s)
- N Mittag
- Institute of Toxicology and Pharmacology, University of Rostock, Rostock, Germany
| | - S Meister
- Department of Neurology, University of Rostock, Rostock, Germany
| | - A M J Berg
- Institute of Toxicology and Pharmacology, University of Rostock, Rostock, Germany
| | - U I Walther
- Institute of Toxicology and Pharmacology, University of Rostock, Rostock, Germany
| |
Collapse
|
49
|
Plouffe DM, Wree M, Du AY, Meister S, Li F, Patra K, Lubar A, Okitsu SL, Flannery EL, Kato N, Tanaseichuk O, Comer E, Zhou B, Kuhen K, Zhou Y, Leroy D, Schreiber SL, Scherer CA, Vinetz J, Winzeler EA. High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission. Cell Host Microbe 2015; 19:114-26. [PMID: 26749441 PMCID: PMC4723716 DOI: 10.1016/j.chom.2015.12.001] [Citation(s) in RCA: 117] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2015] [Revised: 11/13/2015] [Accepted: 12/11/2015] [Indexed: 11/18/2022]
Abstract
Preventing transmission is an important element of malaria control. However, most of the current available methods to assay for malaria transmission blocking are relatively low throughput and cannot be applied to large chemical libraries. We have developed a high-throughput and cost-effective assay, the Saponin-lysis Sexual Stage Assay (SaLSSA), for identifying small molecules with transmission-blocking capacity. SaLSSA analysis of 13,983 unique compounds uncovered that >90% of well-characterized antimalarials, including endoperoxides and 4-aminoquinolines, as well as compounds active against asexual blood stages, lost most of their killing activity when parasites developed into metabolically quiescent stage V gametocytes. On the other hand, we identified compounds with consistent low nanomolar transmission-blocking activity, some of which showed cross-reactivity against asexual blood and liver stages. The data clearly emphasize substantial physiological differences between sexual and asexual parasites and provide a tool and starting points for the discovery and development of transmission-blocking drugs.
Collapse
Affiliation(s)
- David M Plouffe
- The Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA
| | - Melanie Wree
- Division of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Alan Y Du
- Division of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Stephan Meister
- Division of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Fengwu Li
- Division of Infectious Disease, Department of Medicine, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Kailash Patra
- Division of Infectious Disease, Department of Medicine, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Aristea Lubar
- Division of Infectious Disease, Department of Medicine, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Shinji L Okitsu
- Division of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Erika L Flannery
- Division of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Nobutaka Kato
- Broad Institute, 415 Main Street, Cambridge MA 02142
| | - Olga Tanaseichuk
- The Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA
| | - Eamon Comer
- Broad Institute, 415 Main Street, Cambridge MA 02142
| | - Bin Zhou
- The Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA
| | - Kelli Kuhen
- The Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA
| | - Yingyao Zhou
- The Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA
| | - Didier Leroy
- Medicines for Malaria Venture (MMV), PO Box 1826, 20 Route de Pré-Bois, 1215 Geneva 15, Switzerland
| | - Stuart L Schreiber
- Broad Institute, 415 Main Street, Cambridge MA 02142; Department of Chemistry and Chemical Biology, Harvard University, 7 Cambridge Center, Cambridge, MA 02142, USA
| | | | - Joseph Vinetz
- Division of Infectious Disease, Department of Medicine, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Elizabeth A Winzeler
- Division of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
| |
Collapse
|
50
|
Le Manach C, Paquet T, Brunschwig C, Njoroge M, Han Z, Gonzàlez Cabrera D, Bashyam S, Dhinakaran R, Taylor D, Reader J, Botha M, Churchyard A, Lauterbach S, Coetzer TL, Birkholtz LM, Meister S, Winzeler EA, Waterson D, Witty MJ, Wittlin S, Jiménez-Díaz MB, Santos Martínez M, Ferrer S, Angulo-Barturen I, Street LJ, Chibale K. A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines. J Med Chem 2015; 58:8713-22. [PMID: 26502160 DOI: 10.1021/acs.jmedchem.5b01605] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Toward improving pharmacokinetics, in vivo efficacy, and selectivity over hERG, structure-activity relationship studies around the central core of antimalarial imidazopyridazines were conducted. This study led to the identification of potent pyrazolopyridines, which showed good in vivo efficacy and pharmacokinetics profiles. The lead compounds also proved to be very potent in the parasite liver and gametocyte stages, which makes them of high interest.
Collapse
Affiliation(s)
| | | | - Christel Brunschwig
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Observatory 7925, South Africa
| | - Mathew Njoroge
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Observatory 7925, South Africa
| | | | | | - Sridevi Bashyam
- Syngene International Ltd. , Biocon Park, Plot No. 2 & 3, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India
| | - Rajkumar Dhinakaran
- Syngene International Ltd. , Biocon Park, Plot No. 2 & 3, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India
| | - Dale Taylor
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Observatory 7925, South Africa
| | - Janette Reader
- Department of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria , Private bag X20, Hatfield 0028, South Africa
| | - Mariette Botha
- Department of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria , Private bag X20, Hatfield 0028, South Africa
| | - Alisje Churchyard
- Department of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria , Private bag X20, Hatfield 0028, South Africa
| | - Sonja Lauterbach
- Department of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria , Private bag X20, Hatfield 0028, South Africa
| | - Theresa L Coetzer
- Department of Molecular Medicine and Haematology, Wits Research Institute for Malaria, Wits Medical School , 2000 Johannesburg, South Africa
| | - Lyn-Marie Birkholtz
- Department of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria , Private bag X20, Hatfield 0028, South Africa
| | - Stephan Meister
- School of Medicine, Department of Pediatrics, Pharmacology & Drug Discovery, University of California, San Diego (UCSD) , 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Elizabeth A Winzeler
- School of Medicine, Department of Pediatrics, Pharmacology & Drug Discovery, University of California, San Diego (UCSD) , 9500 Gilman Drive, La Jolla, California 92093, United States
| | - David Waterson
- Medicines for Malaria Venture , ICC, Route de Pré-Bois 20, PO Box 1826, 1215 Geneva, Switzerland
| | - Michael J Witty
- Medicines for Malaria Venture , ICC, Route de Pré-Bois 20, PO Box 1826, 1215 Geneva, Switzerland
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute , Socinstrasse 57, 4002 Basel, Switzerland.,University of Basel , 4003 Basel, Switzerland
| | - María-Belén Jiménez-Díaz
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain
| | - María Santos Martínez
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain
| | - Santiago Ferrer
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain
| | - Iñigo Angulo-Barturen
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain
| | | | | |
Collapse
|